Abstract | BACKGROUND: METHODS: Nude mice bearing lung adenocarcinoma (PC-14 or A549 xenografts) were administered NK012 at SN-38-equivalent doses of 5 mg/kg or 30 mg/kg in combination with or without Bv at 5 mg/kg. CPT-11 at a dose of 66.7 mg/kg was administered with or without Bv at a dose of 5 mg/kg in the same experimental model. To evaluate interaction with Bv, the pharmacokinetics and microvessel density in tumors that were treated on each regimen were analyzed. RESULT: In vitro, the growth-inhibitory effect of NK012 was 50-fold more potent than that of CPT-11 and was almost equivalent to that of SN-38. In vivo studies revealed that the combination of NK012 plus Bv had significantly greater antitumor activity against human lung cancer xenografts compared with NK012 alone (PC-14, P=.0261; A549, P<.001). The pharmacokinetic profile of NK012 revealed that coadministration of Bv did not interfere with the accumulation of NK012. CONCLUSIONS: In this study, significant antitumor activity was noted with NK012 in combination with Bv against lung cancer cells. The current results warrant the clinical evaluation of NK012 in lung cancer.
|
Authors | Hirotsugu Kenmotsu, Masahiro Yasunaga, Koichi Goto, Tatsuya Nagano, Jun-ichiro Kuroda, Yoshikatsu Koga, Amane Takahashi, Yutaka Nishiwaki, Yasuhiro Matsumura |
Journal | Cancer
(Cancer)
Vol. 116
Issue 19
Pg. 4597-604
(Oct 01 2010)
ISSN: 0008-543X [Print] United States |
PMID | 20572031
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2010 American Cancer Society. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Phytogenic
- Micelles
- Bevacizumab
- Irinotecan
- Camptothecin
|
Topics |
- Adenocarcinoma
(drug therapy, metabolism)
- Animals
- Antibodies, Monoclonal
(administration & dosage, pharmacokinetics)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Phytogenic
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bevacizumab
- Camptothecin
(analogs & derivatives, pharmacokinetics, therapeutic use)
- Cell Line, Tumor
- Female
- Humans
- Irinotecan
- Lung Neoplasms
(drug therapy, metabolism)
- Mice
- Mice, Inbred BALB C
- Micelles
- Xenograft Model Antitumor Assays
|